Source comparison
Peptides for Ligament Tear Compared: Protocol Comparison
BPC-157 Upregulates growth factor receptors (VEGF, EGF); accelerates collagen type I synthesis 4–6 hours 200–500 mcg Twice daily Proliferative phase (days 3–21) Multiple animal studies; limited human data TB-500 Actin sequestration; promotes cell migration and
This comparison does not assign a generated winner or score.
- BPC-157
- Upregulates growth factor receptors (VEGF, EGF); accelerates collagen type I synthesis
- 4–6 hours
- 200–500 mcg
- Twice daily
- Proliferative phase (days 3–21)
- Multiple animal studies; limited human data
- TB-500
- Actin sequestration; promotes cell migration and angiogenesis; reduces inflammatory cytokines
- ~10 days
- 2–5 mg
- Twice weekly (loading); once weekly (maintenance)
- Inflammatory phase (days 0–5) and remodeling phase (weeks 3–12)
- Animal models + equine clinical use
- Combined Protocol
- Sequential or concurrent administration targeting different repair phases
- Variable
- BPC-157: 250 mcg 2x/day + TB-500: 2mg 2x/week
- As per individual compounds
- All phases
- Observational data; mechanistic rationale strong